• darkblurbg

    Developing therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®


 Dates for financial information and other events
Data pager
Data pager
March 11 − March 12, 2021
SSSD 2021
Scandinavian Society for the Study of Diabetes, 2021 virtual conference
March 11, 2021
Erik Penser Bank Corporate Market Day
Company presentation by CEO Ulf Hannelius.
March 31, 2021
Quarterly Report II
Quarterly Report 2 2020/2021
April 13 − April 14, 2021
Drug Discovery & Development with AI & ML
3rd Annual Forum - Online Conference

Company Presentation

 February 8, 2021

The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 1 20/21


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research